Regulatory Expectations for Bayesian Methods in Drug and Biologic Clinical Trials: A Practical Perspective on FDA's 2026 Draft Guidance

TL;DR

This paper interprets the FDA's 2026 draft guidance on Bayesian methods in clinical trials, emphasizing justification, transparency, and calibration of Bayesian designs for regulatory acceptance.

Contribution

It provides a practical synthesis of the draft guidance, illustrating Bayesian design considerations and offering an actionable checklist for sponsors.

Findings

Bayesian designs should be justified with explicit success criteria.

Calibration to traditional error rates is feasible for Bayesian methods.

Examples include platform trials and external control use cases.

Abstract

The U.S. Food and Drug Administration (FDA) released a landmark draft guidance in January 2026 on the use of Bayesian methodology to support primary inference in clinical trials of drugs and biological products. For sponsors, the central message is not merely that ``Bayes is allowed,'' but that Bayesian designs should be justified through explicit success criteria, thoughtful priors (especially when borrowing external information), prospective operating-characteristic evaluation (often via simulation when simulation is used), and computational transparency suitable for regulatory review. This paper provides a practical, regulatory-oriented synthesis of the draft guidance, highlighting where Bayesian designs can be calibrated to traditional frequentist error-rate targets and where, with sponsor--FDA agreement, alternative Bayesian operating metrics may be appropriate. We illustrate expectations through examples discussed in the guidance (e.g., platform trials, external/nonconcurrent controls, pediatric extrapolation) and conclude with an actionable checklist for planning documents and submission packages.